Patients
cancer
CANCER, BRAIN METASTASIS
Patient selection criteria were identical to those used for the fixed-dose Q2W schedule (Patients were excluded if they were receiving concurrent cancer treatment, had previously received CEACAM5-targeted or maytansinoid-containing regimens, or had brain metastasis, poor organ function, low bone marrow reserve, or life expectancy <12 weeks.